Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Research & Development: HK$16 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shenzhen Neptunus Interlong Bio-Technique Co Research & Development?

Shenzhen Neptunus Interlong Bio-Technique Co HKSE:08329 -5.71% Research & Development is HK$16 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shenzhen Neptunus Interlong Bio-Technique Co's Research & Development for the six months ended in Jun. 2026 was HK$16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was HK$16 Mil.

Shenzhen Neptunus Interlong Bio-Technique Co  (HKSE:08329) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shenzhen Neptunus Interlong Bio-Technique Co Research & Development Related Terms

Shenzhen Neptunus Interlong Bio-Technique Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Neptunus Interlong Bio-Technique Co Research & Development Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.37 33.40 51.05 35.92 35.44

Shenzhen Neptunus Interlong Bio-Technique Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.57 16.35 18.10 17.33 16.13

Shenzhen Neptunus Interlong Bio-Technique Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$16 Mil mean?
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Research & Development of HK$16 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Research & Development too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Research & Development is HK$16 Mil.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Research & Development compare to ZTS?
Shenzhen Neptunus Interlong Bio-Technique Co's Research & Development of HK$16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. Shenzhen Neptunus Interlong Bio-Technique Co's current Research & Development is HK$16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current Research & Development is HK$16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Research & Development is HK$16 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Address 979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.